Men with blood group O are far less likely to suffer a recurrence of cancer after prostate tumour surgery than men with other blood types, researchers report.
A standard treatment for localised prostate cancer is to remove the whole gland, a procedure called radical prostatectomy, but this fails to stop the cancer in nearly a third of patients.
Japanese researchers looked at 555 men who had had radical prostatectomy, examining their case 52 months on average after the operation.
Patients with blood group O were 35 percent less likely to have a recurrence of cancer compared with patients with blood group A, they found.
"This is the first time that anyone has shown that prostate cancer recurrence can vary with blood group," Yoshio Ohno of Tokyo Medical University said in a press release.
Read the complete story here: http://bit.ly/1kYgxSp
Source: Medicalxpress
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More